Gamida Cell Ltd. (GMDA)
- Previous Close
0.0327 - Open
0.0395 - Bid --
- Ask --
- Day's Range
0.0327 - 0.0327 - 52 Week Range
0.0080 - 2.5100 - Volume
23,036,893 - Avg. Volume
9,670,277 - Market Cap (intraday)
4.337M - Beta (5Y Monthly) 1.03
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8200 - Earnings Date Mar 25, 2024 - Mar 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.00
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.
www.gamida-cell.comRecent News: GMDA
Performance Overview: GMDA
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GMDA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GMDA
Valuation Measures
Market Cap
2.62M
Enterprise Value
55.93M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.82
Price/Book (mrq)
--
Enterprise Value/Revenue
20.92
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-41.47%
Return on Equity (ttm)
-1,103.79%
Revenue (ttm)
673k
Net Income Avi to Common (ttm)
-76.95M
Diluted EPS (ttm)
-0.8200
Balance Sheet and Cash Flow
Total Cash (mrq)
60.43M
Total Debt/Equity (mrq)
22,308.38%
Levered Free Cash Flow (ttm)
-54.19M